Abstract
The successful treatment of certain autoimmune conditions with the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Autoimmune Diseases / drug therapy
-
Autoimmune Diseases / immunology
-
Cytokine Receptor gp130 / immunology*
-
Humans
-
Inflammation / drug therapy
-
Inflammation / immunology
-
Interleukin-6 / immunology*
-
Neoplasms / immunology
-
Receptors, Interleukin-6 / genetics
-
Receptors, Interleukin-6 / immunology*
-
Signal Transduction / immunology*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Interleukin-6
-
Receptors, Interleukin-6
-
Cytokine Receptor gp130
-
tocilizumab